1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Varambally S, Dhanasekaran SM, Zhou M,
Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt
RG, Otte AP, et al: The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature. 419:624–629. 2002.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Rayford W, Noble MJ, Austenfeld MA, Weigel
J, Mebust WK and Shah GV: Muscarinic cholinergic receptors promote
growth of human prostate cancer cells. Prostate. 30:160–166. 1997.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Witte LP, Chapple CR, de la Rosette JJ and
Michel MC: Cholinergic innervation and muscarinic receptors in the
human prostate. Eur Urol. 54:326–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
6
|
Shah N, Khurana S, Cheng K and Raufman
J-P: Muscarinic receptors and ligands in cancer. Am J Physiol Cell
Physiol. 296:C221–C232. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ventura S, Pennefather J and Mitchelson F:
Cholinergic innervation and function in the prostate gland.
Pharmacol Ther. 94:93–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
8
|
White CW, Short JL, Haynes JM, Matsui M
and Ventura S: Contractions of the mouse prostate elicited by
acetylcholine are mediated by M(3) muscarinic receptors. J
Pharmacol Exp Ther. 339:870–877. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ashida S, Orloff MS, Bebek G, Zhang L,
Zheng P, Peehl DM and Eng C: Integrated analysis reveals critical
genomic regions in prostate tumor microenvironment associated with
clinicopathologic phenotypes. Clin Cancer Res. 18:1578–1587. 2012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Varambally S, Yu J, Laxman B, Rhodes DR,
Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, et
al: Integrative genomic and proteomic analysis of prostate cancer
reveals signatures of metastatic progression. Cancer Cell.
8:393–406. 2005. View Article : Google Scholar : PubMed/NCBI
|
11
|
Irizarry RA, Hobbs B, Collin F,
Beazer-Barclay YD, Antonellis KJ, Scherf U and Speed TP:
Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics. 4:249–264.
2003. View Article : Google Scholar : PubMed/NCBI
|
12
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy - analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Smyth GK: Linear models and empirical
bayes methods for assessing differential expression in microarray
experiments. Stat Appl Genet Mol Biol. 3:Article 3. 2004.PubMed/NCBI
|
14
|
Smyth GK: Limma: linear models for
microarray data. Bioinformatics and Computational Biology Solutions
using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry
R and Huber W: (New York, NY). Springer. 397–420. 2005. View Article : Google Scholar
|
15
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: The Gene Ontology Consortium: Gene ontology: Tool for the
unification of biology. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000. View Article : Google Scholar : PubMed/NCBI
|
17
|
Huang DW, Sherman BT, Tan Q, Collins JR,
Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki
RA: The DAVID Gene Functional Classification Tool: A novel
biological module-centric algorithm to functionally analyze large
gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI
|
18
|
von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
19
|
He X and Zhang J: Why do hubs tend to be
essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhang B, Kirov S and Snoddy J: WebGestalt:
An integrated system for exploring gene sets in various biological
contexts. Nucleic Acids Res. 33(Web Server): W741–8. 2005.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Kohl M, Wiese S and Warscheid B:
Cytoscape: Software for visualization and analysis of biological
networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37(Suppl 4): S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
23
|
Gschwind A, Fischer OM and Ullrich A: The
discovery of receptor tyrosine kinases: Targets for cancer therapy.
Nat Rev Cancer. 4:361–370. 2004. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Prenzel N, Fischer OM, Streit S, Hart S
and Ullrich A: The epidermal growth factor receptor family as a
central element for cellular signal transduction and
diversification. Endocr Relat Cancer. 8:11–31. 2001. View Article : Google Scholar : PubMed/NCBI
|
25
|
Bjorge JD, Chan T-O, Antczak M, Kung H-J
and Fujita DJ: Activated type I phosphatidylinositol kinase is
associated with the epidermal growth factor (EGF) receptor
following EGF stimulation. Proc Natl Acad Sci USA. 87:3816–3820.
1990. View Article : Google Scholar : PubMed/NCBI
|
26
|
Qin J, Xie Y, Wang B, Hoshino M, Wolff DW,
Zhao J, Scofield MA, Dowd FJ, Lin MF and Tu Y: Upregulation of
PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer
metastasis. Oncogene. 28:1853–1863. 2009. View Article : Google Scholar : PubMed/NCBI
|
27
|
Shukla S, Maclennan GT, Hartman DJ, Fu P,
Resnick MI and Gupta S: Activation of PI3K-Akt signaling pathway
promotes prostate cancer cell invasion. Int J Cancer.
121:1424–1432. 2007. View Article : Google Scholar : PubMed/NCBI
|
28
|
Slack BE: The m3 muscarinic acetylcholine
receptor is coupled to mitogen-activated protein kinase via protein
kinase C and epidermal growth factor receptor kinase. Biochem J.
348:381–387. 2000. View Article : Google Scholar : PubMed/NCBI
|
29
|
Nie D, Guo Y, Yang D, Tang Y, Chen Y, Wang
MT, Zacharek A, Qiao Y, Che M and Honn KV: Thromboxane A2 receptors
in prostate carcinoma: Expression and its role in regulating cell
motility via small GTPase Rho. Cancer Res. 68:115–121. 2008.
View Article : Google Scholar : PubMed/NCBI
|
30
|
Katz M, Amit I and Yarden Y: Regulation of
MAPKs by growth factors and receptor tyrosine kinases. Biochim
Biophys Acta. 1773:1161–1176. 2007. View Article : Google Scholar : PubMed/NCBI
|
31
|
Naor Z, Benard O and Seger R: Activation
of MAPK cascades by G-protein-coupled receptors: The case of
gonadotropin-releasing hormone receptor. Trends Endocrinol Metab.
11:91–99. 2000. View Article : Google Scholar : PubMed/NCBI
|
32
|
Carracedo A, Ma L, Teruya-Feldstein J,
Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma
SC, et al: Inhibition of mTORC1 leads to MAPK pathway activation
through a PI3K-dependent feedback loop in human cancer. J Clin
Invest. 118:3065–3074. 2008.PubMed/NCBI
|
33
|
Wang J, Kobayashi T, Floc'h N, Kinkade CW,
Aytes A, Dankort D, Lefebvre C, Mitrofanova A, Cardiff RD, McMahon
M, et al: B-Raf activation cooperates with PTEN loss to drive c-Myc
expression in advanced prostate cancer. Cancer Res. 72:4765–4776.
2012. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ling M-T, Wang X, Ouyang X-S, Lee TK, Fan
TY, Xu K, Tsao SW and Wong YC: Activation of MAPK signaling pathway
is essential for Id-1 induced serum independent prostate cancer
cell growth. Oncogene. 21:8498–8505. 2002. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kinkade CW, Castillo-Martin M, Puzio-Kuter
A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL,
Cordon-Cardo C, et al: Targeting AKT/mTOR and ERK MAPK signaling
inhibits hormone-refractory prostate cancer in a preclinical mouse
model. J Clin Invest. 118:3051–3064. 2008.PubMed/NCBI
|
36
|
Grandori C, Cowley SM, James LP and
Eisenman RN: The Myc/Max/Mad network and the transcriptional
control of cell behavior. Annu Rev Cell Dev Biol. 16:653–699. 2000.
View Article : Google Scholar : PubMed/NCBI
|
37
|
Ellwood-Yen K, Graeber TG, Wongvipat J,
Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV and Sawyers CL:
Myc-driven murine prostate cancer shares molecular features with
human prostate tumors. Cancer Cell. 4:223–238. 2003. View Article : Google Scholar : PubMed/NCBI
|
38
|
Sun C, Dobi A, Mohamed A, Li H,
Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan
G, Whitman E, et al: TMPRSS2-ERG fusion, a common genomic
alteration in prostate cancer activates C-MYC and abrogates
prostate epithelial differentiation. Oncogene. 27:5348–5353. 2008.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Rokhlin OW, Scheinker VS, Taghiyev AF,
Bumcrot D, Glover RA and Cohen MB: MicroRNA-34 mediates
AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol
Ther. 7:1288–1296. 2008. View Article : Google Scholar : PubMed/NCBI
|
40
|
Corney DC, Flesken-Nikitin A, Godwin AK,
Wang W and Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of
p53 and cooperate in control of cell proliferation and
adhesion-independent growth. Cancer Res. 67:8433–8438. 2007.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Notari M, Neviani P, Santhanam R, Blaser
BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci
G, et al: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential
by regulating MYC mRNA translation. Blood. 107:2507–2516. 2006.
View Article : Google Scholar : PubMed/NCBI
|